Consensus Genmab A/S

Equities

GMAB

DK0010272202

Market Closed - Nasdaq Copenhagen 16:20:00 14/06/2024 BST 5-day change 1st Jan Change
1,832 DKK +0.47% Intraday chart for Genmab A/S -5.05% -14.97%

Evolution of the average Target Price on Genmab A/S

Price target over the last 5 years

History of analyst recommendation changes

40f0091f35efdca2254bb093621b.my8bB7FSg2JIOiGgHtrm24ZgsCBDd83fqu7Q7gbL8Tk.w15xU8Jqti8XXlf0aIurnMgFwWFyOqeynZuK10uYg3__XlxW5QrUDz91ZA~57ce80de300723d1e84a8c6dfb102ee6
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT
GENMAB : A good start to 2024; guidance unchanged Alphavalue
GENMAB : Genmab is available at a bargain price Alphavalue
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46 MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks Alphavalue
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded Alphavalue
GENMAB : Factoring in some caution Alphavalue
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact Alphavalue
BTIG Starts Genmab at Buy With $44 Price Target MT
GENMAB : A good Q2 + improved sales guidance Alphavalue
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss Alphavalue
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry Alphavalue
HC Wainwright Adjusts Price Target on Genmab to $46 From $51, Maintains Buy Rating MT
Morgan Stanley Trims Price Target on Genmab to $33 From $34, Maintains Underweight Rating MT
GENMAB : Promising 2022; even softer 2023 guidance isn’t a worry Alphavalue
Morgan Stanley Adjusts Price Target on Genmab to $34 From $35, Keeps Underweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,832 DKK
Average target price
2,464 DKK
Spread / Average Target
+34.46%
High Price Target
3,000 DKK
Spread / Highest target
+63.71%
Low Price Target
1,600 DKK
Spread / Lowest Target
-12.69%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genmab A/S

Truist Securities
alphavalue Anas Patel
BMO Capital
RBC Capital Markets
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
William Blair & Co.
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW